More Articles

Washington State legislation on biosimilars Policies & Legislation | Posted 07/02/2014

Biologicals manufacturers represented by the Biotechnology Industry Association (BIO) and the Washington Biotechnology & Biomedical Association have welcomed proposed Washington State legislati...

Effects of income, competition and procurement on drug prices in emerging markets Generics/Research | Posted 07/02/2014

Drugs are least affordable relative to income in low-income countries, according to an analysis of income, competition and procurement on drug prices in emerging markets [1].

Mylan launches trastuzumab ‘similar biologic’ in India Biosimilars/News | Posted 07/02/2014

Generics giant Mylan announced on 3 February 2014 that its subsidiary, Mylan Pharmaceuticals Private Limited, had launched its trastuzumab ‘similar biologic’ Hertraz to the Indian market.

Forest Labs files lawsuit to stop generic memantine Generics/News | Posted 07/02/2014

Forest Laboratories and Forest Laboratories Holdings (Forest) announced on 31 January 2014 that the company has filed a lawsuit in the US against several generics makers for their generic versions...

Biosimilars: what physicians need to know Reports | Posted 07/02/2014

A biosimilar is a medicinal product that is similar to a biological medicinal product that has already been authorized. Biologicals are comprised of proteins, such as hormones (growth hormones, ins...

Epirus and Ranbaxy sign agreement for infliximab 'similar biologic' Biosimilars/News | Posted 07/02/2014

Epirus Switzerland, a subsidiary of US-based Epirus Biopharmaceuticals, and India-based Ranbaxy Laboratories (Ranbaxy) announced on 9 January 2013 that the two companies had signed a licensing agre...

Improving access to HCV treatment in developing countries Biosimilars/Research | Posted 31/01/2014

Hepatitis C virus (HCV) infection affects 150–180 million people worldwide each year, killing an estimated 350,000. The considerable cost of treatment – US$ 10,000–US$20,000 per patient for a 48-we...

Biologicals sales quadruple from 2002 to 2017 Biosimilars/General | Posted 31/01/2014

Biologicals are outstripping regular pharmaceuticals in terms of growth and taking a bigger and bigger chunk of overall drug sales. Increasingly, biosimilars and non-originator biologicals are also...